首页> 美国卫生研究院文献>other >Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells
【2h】

Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cells

机译:从人的多能干细胞生物工程化机电功能的微型心室腔

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tissue engineers and stem cell biologists have made exciting progress toward creating simplified models of human heart muscles or aligned monolayers to help bridge a longstanding gap between experimental animals and clinical trials. However, no existing human in vitro systems provide the direct measures of cardiac performance as a pump. Here, we developed a next-generation in vitro biomimetic model of pumping human heart chamber, and demonstrated its capability for pharmaceutical testing. From human pluripotent stem cell (hPSC)-derived ventricular cardiomyocytes (hvCM) embedded in collagen-based extracellular matrix hydrogel, we engineered a three-dimensional (3D) electro-mechanically coupled, fluid-ejecting miniature human ventricle-like cardiac organoid chamber (hvCOC). Structural characterization showed organized sarcomeres with myofibrillar microstructures. Transcript and RNA-seq analyses revealed upregulation of key Ca2+-handling, ion channel, and cardiac-specific proteins in hvCOC compared to lower-order 2D and 3D cultures of the same constituent cells. Clinically-important, physiologically complex contractile parameters such as ejection fraction, developed pressure, and stroke work, as well as electrophysiological properties including action potential and conduction velocity were measured: hvCOC displayed key molecular and physiological characteristics of the native ventricle, and showed expected mechanical and electrophysiological responses to a range of pharmacological interventions (including positive and negative inotropes). We conclude that such “human-heart-in-a-jar” technology could facilitate the drug discovery process by providing human-specific preclinical data during early stage drug development.
机译:组织工程师和干细胞生物学家在创建简化的人类心肌模型或对齐的单层模型以帮助弥合实验动物与临床试验之间的长期鸿沟方面取得了令人兴奋的进展。但是,没有现有的人体体外系统可以直接测量心脏功能。在这里,我们开发了一种泵浦人体心脏腔的下一代体外仿生模型,并展示了其进行药物测试的能力。从嵌入在基于胶原的细胞外基质水凝胶中的人多能干细胞(hPSC)衍生的心室心肌细胞(hvCM)中,我们设计了三维(3D)机电耦合,液体喷射的微型人心室样心脏类器官腔( hvCOC)。结构表征显示具有肌原纤维微结构的组织肉瘤。转录本和RNA-seq分析显示,与相同组成细胞的低阶2D和3D培养相比,hvCOC中关键的Ca 2 + 处理,离子通道和心脏特异性蛋白上调。测量了临床上重要的生理学上复杂的收缩参数,例如射血分数,发达的压力和中风功,以及包括动作电位和传导速度的电生理特性:hvCOC显示了天然心室的关键分子和生理特征,并显示了预期的机械和对一系列药理干预措施(包括正性和负性肌力药)的电生理反应。我们得出的结论是,这种“罐中人心”技术可以通过在早期药物开发过程中提供特定于人类的临床前数据来促进药物发现过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号